AR097792A1 - Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple - Google Patents
Terapia combinada con laquinimod para el tratamiento de la esclerosis múltipleInfo
- Publication number
- AR097792A1 AR097792A1 ARP140103582A ARP140103582A AR097792A1 AR 097792 A1 AR097792 A1 AR 097792A1 AR P140103582 A ARP140103582 A AR P140103582A AR P140103582 A ARP140103582 A AR P140103582A AR 097792 A1 AR097792 A1 AR 097792A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- pharmaceutical composition
- compound
- formula
- amount
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 9
- 229960004577 laquinimod Drugs 0.000 title abstract 9
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 7
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 230000003113 alkalizing effect Effects 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229960003194 meglumine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000000049 pigment Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883698P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097792A1 true AR097792A1 (es) | 2016-04-13 |
Family
ID=52740749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103582A AR097792A1 (es) | 2013-09-27 | 2014-09-26 | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150094332A1 (enExample) |
| EP (1) | EP3049075A4 (enExample) |
| JP (1) | JP2016533323A (enExample) |
| KR (1) | KR20160085757A (enExample) |
| CN (1) | CN105848653A (enExample) |
| AR (1) | AR097792A1 (enExample) |
| AU (1) | AU2014342917A1 (enExample) |
| BR (1) | BR112016006582A2 (enExample) |
| CA (1) | CA2925493A1 (enExample) |
| EA (1) | EA201690673A1 (enExample) |
| IL (1) | IL244620A0 (enExample) |
| MX (1) | MX2016003763A (enExample) |
| SG (1) | SG11201602175VA (enExample) |
| TW (1) | TW201601722A (enExample) |
| UY (1) | UY35748A (enExample) |
| WO (1) | WO2015065628A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
| CN107308162A (zh) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
-
2014
- 2014-09-26 EP EP14857795.0A patent/EP3049075A4/en not_active Withdrawn
- 2014-09-26 TW TW103133660A patent/TW201601722A/zh unknown
- 2014-09-26 BR BR112016006582A patent/BR112016006582A2/pt not_active IP Right Cessation
- 2014-09-26 US US14/498,024 patent/US20150094332A1/en not_active Abandoned
- 2014-09-26 AR ARP140103582A patent/AR097792A1/es unknown
- 2014-09-26 KR KR1020167011039A patent/KR20160085757A/ko not_active Withdrawn
- 2014-09-26 AU AU2014342917A patent/AU2014342917A1/en not_active Abandoned
- 2014-09-26 UY UY0001035748A patent/UY35748A/es not_active Application Discontinuation
- 2014-09-26 CN CN201480053575.8A patent/CN105848653A/zh active Pending
- 2014-09-26 MX MX2016003763A patent/MX2016003763A/es unknown
- 2014-09-26 EA EA201690673A patent/EA201690673A1/ru unknown
- 2014-09-26 JP JP2016516547A patent/JP2016533323A/ja not_active Withdrawn
- 2014-09-26 SG SG11201602175VA patent/SG11201602175VA/en unknown
- 2014-09-26 CA CA2925493A patent/CA2925493A1/en active Pending
- 2014-09-26 WO PCT/US2014/057705 patent/WO2015065628A2/en not_active Ceased
-
2016
- 2016-03-15 IL IL244620A patent/IL244620A0/en unknown
- 2016-05-31 US US15/169,139 patent/US20160271094A1/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,214 patent/US20170304253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085757A (ko) | 2016-07-18 |
| CA2925493A1 (en) | 2015-05-07 |
| MX2016003763A (es) | 2016-10-28 |
| UY35748A (es) | 2015-04-30 |
| US20150094332A1 (en) | 2015-04-02 |
| IL244620A0 (en) | 2016-04-21 |
| US20170304253A1 (en) | 2017-10-26 |
| EP3049075A4 (en) | 2017-05-03 |
| WO2015065628A2 (en) | 2015-05-07 |
| AU2014342917A1 (en) | 2016-04-21 |
| US20160271094A1 (en) | 2016-09-22 |
| EP3049075A2 (en) | 2016-08-03 |
| EA201690673A1 (ru) | 2016-08-31 |
| WO2015065628A3 (en) | 2015-10-29 |
| CN105848653A (zh) | 2016-08-10 |
| BR112016006582A2 (pt) | 2017-08-01 |
| TW201601722A (zh) | 2016-01-16 |
| SG11201602175VA (en) | 2016-04-28 |
| JP2016533323A (ja) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| CA3253937A1 (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| NZ707640A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| AR091706A1 (es) | Formulaciones de laquinimod sin agentes alcalinizantes | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| AR097792A1 (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple | |
| BR112015019307A8 (pt) | derivados de ácido butanóico substituído com bisfenila, seus usos, e composição farmacêutica | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |